Metabolic effects of citrate- vs bicarbonate-based substitution fluid in continuous venovenous hemofiltration: a prospective sequential cohort study.
BACKGROUND
Studies investigating the metabolic effects of citrate-based substitution fluids are lacking. This study aims to compare the effect of citrate- vs bicarbonate-based substitution fluid used during continuous venovenous hemofiltration (CVVH) for acute kidney injury on acid-base balance and electrolytes in critically ill patients.


METHODS
This was a prospective sequential cohort study in patients with a contraindication for systemic anticoagulation. The first cohort was treated by bicarbonate-based CVVH (n = 10) and the second cohort was treated by CVVH with citrate-based substitution fluid (n = 19). Flow of the latter was coupled to blood flow, and ionized calcium concentrations were monitored and kept constant by calcium-glubionate infusion.


RESULTS
No major differences between the 2 groups were found in baseline acid-base parameters. In both groups, arterial pH increased after initiation of treatment and normalized on the average within 18 hours in either group. No differences were found in bicarbonate concentrations. Electrolyte control was comparable for the groups.


CONCLUSIONS
Citrate-based substitution fluid is comparable to bicarbonate-based substitution fluid during CVVH in critically ill patients with acute kidney injury, concerning acid-base balance and electrolyte control. This implies complete conversion of citrate to bicarbonate in the patients studied.
Aman
Jurjan
J
Department of Intensive Care, VU University Medical Centre, PO Box 7057, 1007 MB Amsterdam, The Netherlands. jurjanaman@live.nl
Nurmohamed
S Azam
SA
Vervloet
Marc G
MG
Groeneveld
A B Johan
AB
D000136:Acid-Base Equilibrium / Q000187:drug effects*; D058186:Acute Kidney Injury / Q000188:drug therapy* / Q000378:metabolism; D000925:Anticoagulants / Q000627:therapeutic use*; D001639:Bicarbonates / Q000627:therapeutic use*; D002021:Buffers; D002118:Calcium / Q000378:metabolism; D019343:Citric Acid / Q000627:therapeutic use*; D016638:Critical Illness; D004573:Electrolytes / Q000378:metabolism; D005260:Female; D006440:Hemofiltration / Q000379:methods*; D006801:Humans; D007362:Intensive Care Units; D008297:Male; D008875:Middle Aged; D019370:Observation; D009942:Organometallic Compounds / Q000008:administration & dosage; D011446:Prospective Studies; D016896:Treatment Outcome; D014312:Trisaccharides / Q000008:administration & dosage
D000925:Anticoagulants; D001639:Bicarbonates; D002021:Buffers; D004573:Electrolytes; D009942:Organometallic Compounds; D014312:Trisaccharides; D019343:Citric Acid; C042131:calcium glubionate; D002118:Calcium